Literature DB >> 3409178

Late recurrences in long-term survivors of germ cell neoplasms.

M J DeLeo1, F A Greco, J D Hainsworth, D H Johnson.   

Abstract

Patients with germ cell neoplasms who are in complete remission 2 years after treatment have a very high probability of cure, and reports of recurrences occurring after 2 years are rare. Of 81 testicular cancer patients treated for advanced disease at Vanderbilt University between 1970 and 1985, five developed a recurrent or metachronous germinal tumor 58 to 195 months after the initial treatment. Only two of these patients had received prior cisplatin-based combination chemotherapy. Four patients had unfavorable prognostic features when tumor recurrence was diagnosed. All five patients responded to salvage chemotherapy, although there were only two complete responses. The extent of disease was a significant factor in predicting response to salvage therapy. The possible mechanisms of development of a late recurrence of germinal neoplasms include the following: (1) malignant degeneration of mature teratoma to germinal malignancy; (2) growth of an occult testicular tumor not eliminated by chemotherapy due to the presence of a blood-testicular barrier; (3) development of a second primary germ cell neoplasm; or (4) late relapse due to persistent microscopic viable tumor with an atypical less aggressive biologic behavior. "Cured" germ cell tumor patients need careful follow-up beyond 2 years. At a minimum, these patients should be seen annually. Patients found to have teratomas following cisplatin-based chemotherapy should probably undergo more frequent evaluations.

Entities:  

Mesh:

Year:  1988        PMID: 3409178     DOI: 10.1002/1097-0142(19880901)62:5<985::aid-cncr2820620524>3.0.co;2-8

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

Review 1.  Late relapse of testicular cancer.

Authors:  Martin E Lipphardt; Peter Albers
Journal:  World J Urol       Date:  2004-04-03       Impact factor: 4.226

2.  Improved prognosis of intracranial non-germinoma germ cell tumors with multimodality therapy.

Authors:  P L Robertson; R C DaRosso; J C Allen
Journal:  J Neurooncol       Date:  1997-03       Impact factor: 4.130

3.  Cost- and risk-benefit considerations in the management of clinical stage I nonseminomatous testicular tumors.

Authors:  J Baniel; B J Roth; R S Foster; J P Donohue
Journal:  Ann Surg Oncol       Date:  1996-01       Impact factor: 5.344

4.  Remission of recurrent mature teratoma with interferon therapy.

Authors:  D Ornadel; A Wilson; C Trask; J Ledermann
Journal:  J R Soc Med       Date:  1995-09       Impact factor: 5.344

5.  Recurrence of immature ovarian teratoma as malignant follicular carcinoma with liver and peritoneal metastasis 22 years after completion of initial treatment.

Authors:  Nicholas Brian Shannon; Norman Hok Ling Chan; Melissa Ching Ching Teo
Journal:  BMJ Case Rep       Date:  2017-10-24

6.  Osteolytic bone destruction resulting from relapse of a testicular tumour 23 years after inguinal orchiectomy and adjuvant chemotherapy: a case report.

Authors:  Christos Kalaitzis; Athanasios Bantis; Georgios Tsakaldimis; Stylianos Giannakopoulos; Efthimios Sivridis; Stavros Touloupidis
Journal:  J Med Case Rep       Date:  2009-07-31

7.  Mixed or metachronous germ-cell tumor?

Authors:  Kyu-Won Shim; Dong-Seok Kim; Joong-Uhn Choi
Journal:  Childs Nerv Syst       Date:  2006-12-23       Impact factor: 1.532

8.  Cervical mature teratoma 17 years after initial treatment of testicular teratocarcinoma: report of a late relapse.

Authors:  Ramesh Omranipour; Mina Alavion
Journal:  World J Surg Oncol       Date:  2007-01-04       Impact factor: 2.754

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.